DS
OCUL icon

Dudley & Shanley’s Ocular Therapeutix OCUL Stock Holding History

Dudley & Shanley’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,000
Closed -$152K – 35
2025
Q3 		$152K Sell
13,000
-3,400
-21% -$40.7K 0.02% 31
2025
Q2 		$152K Buy
16,400
+200
+1% +$1.56K 0.02% 35
2025
Q1 		$119K Hold
16,200
– – 0.02% 35
2024
Q4 		$138K Hold
16,200
– – 0.02% 36
2024
Q3 		$141K Hold
16,200
– – 0.02% 35
2024
Q2 		$111K Buy
+16,200
New +$100K 0.02% 35

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dudley & Shanley's OCUL Position: Q4 2025 in Review

Dudley & Shanley sold out of Ocular Therapeutix (OCUL) in Q4 2025, closing a stake of 13,000 shares — an estimated $152K sold.

Dudley & Shanley first reported a position in OCUL in Q2 2024 and held it in 6 quarters. The position peaked at $152K in Q2 2025. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

  • Dudley & Shanley reported no remaining Ocular Therapeutix position as of Q4 2025 after selling out during the quarter.
  • Dudley & Shanley sold 13,000 Ocular Therapeutix shares in Q4 2025, an estimated $152K.
  • Dudley & Shanley first reported a position in Ocular Therapeutix in Q2 2024 and held it in 6 quarters.
  • Dudley & Shanley's Ocular Therapeutix position peaked at $152K in Q2 2025.
  • 249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Dudley & Shanley's 13F filing for Q4 2025, filed 9 Jan 2026.